How to Patent an Idea in Australia in 2026, Step-by-step, Costs & Patent Term Extensions

Last updated: 19 May 2026

Understanding how to patent an idea in Australia has never been more important, or more nuanced, than it is right now. IP Australia refreshed its Patent Manual on 16 March 2026, introducing updated examiner practice on computer-implemented inventions, revised excess-claims reminder processes, and important changes to the way patent term extension (PTE) applications are assessed in the wake of the Full Federal Court’s decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd.

Whether you are a startup founder protecting a first product, an in-house counsel managing a portfolio, or a pharmaceutical R&D team navigating PTE strategy, this guide walks through every stage of the Australian patent filing process, from prior-art searching and provisional applications to grant, maintenance and international expansion via the PCT pathway. All statutory references below are to the Patents Act 1990 (Cth) unless stated otherwise.

How to Patent an Idea in Australia, Quick 60-Second Checklist

Before diving into detail, here is an at-a-glance roadmap of the patent filing steps in Australia. Each step is expanded in full below.

1. Confirm your idea is patentable, it must be a manner of manufacture that is novel, involves an inventive step, and is useful (s 18, Patents Act 1990).
2. Conduct a prior-art and novelty search, use AusPat and international databases before committing to drafting costs.
3. Settle ownership and assignment, ensure inventorship and entitlement are documented, especially for employer-employee inventions.
4. File a provisional application (optional but recommended), secures a priority date for 12 months; official fee under AUD 250.
5. File a complete (standard) application, within 12 months of the provisional; include a full specification, claims and abstract.
6. Request examination, must be requested; IP Australia currently takes roughly 6–12 months to issue a first report.
7. Respond to examination objections, address novelty, inventive-step or subject-matter concerns within the statutory deadline (12 months from the first report).
8. Acceptance, advertisement and grant, once accepted, the application is advertised for opposition; grant follows if no opposition succeeds.
9. Pay renewal fees and maintain the patent, annual renewal fees apply from the 5th anniversary; the standard patent term is 20 years from the filing date.
10. Consider PTE (pharmaceutical applicants), if a pharmaceutical substance has been included on the Australian Register of Therapeutic Goods (ARTG), a patent term extension of up to 5 years may be available under s 70 of the Act.

Step-by-Step Patent Filing Process in Australia

Step 1, Decide Whether a Patent Is the Right Protection

A patent protects a device, substance, method or process that is new, inventive and useful. It does not protect artistic works (copyright), brand names (trade marks) or the visual appearance of a product (design registration). The threshold question is whether your idea involves a concrete, technical solution rather than an abstract concept. Under s 18(1) of the Patents Act 1990, a patentable invention must be a “manner of manufacture”, a formulation inherited from the Statute of Monopolies 1623 and interpreted by High Court and Federal Court authority over decades.

If your idea is purely a business method, a mathematical algorithm or a presentation of information, it will face subject-matter objections. If it involves software or a computer-implemented process, the IP Australia Patent Manual update of 16 March 2026 provides revised guidance on how examiners should assess whether the claimed invention delivers a technical contribution beyond the mere implementation of an abstract idea on generic hardware.

Step 2, Conduct a Prior-Art and Novelty Search

A thorough prior-art search reduces the risk of investing in an application that will be refused for lack of novelty. IP Australia’s free AusPat database allows searching of Australian patents and published applications. International databases, including the European Patent Office’s Espacenet, WIPO’s PATENTSCOPE and Google Patents, should also be reviewed, because Australian novelty is assessed against a worldwide prior-art base.

Industry observers recommend that applicants budget for a professional search when the commercial stakes justify it. A patent attorney search typically costs AUD 2,000–5,000, depending on the technology field, but it can save tens of thousands in wasted prosecution costs later.

Step 3, Ownership and Assignment

Before filing, confirm who owns the invention. Under Australian law, the default position is that the inventor is the first owner, unless a valid employment contract or assignment agreement provides otherwise. Joint inventorship arrangements, university research collaborations and contractor relationships should all be documented in writing before any application is filed. Disputes over entitlement can delay or invalidate a granted patent.

Step 4, Drafting the Patent Specification and Claims

The specification is the heart of a patent application. It must describe the invention in sufficient detail that a person skilled in the relevant art could reproduce it (s 40(2)(a)). The claims define the legal boundaries of the monopoly sought. Pharmaceutical applicants should pay particular attention to claim structure: broad genus claims covering a class of compounds, narrower species claims for lead molecules, and method-of-treatment claims can each serve a distinct commercial purpose in lifecycle management.

Practical drafting principles that reduce the risk of examiner objections include clearly linking every claim element to a disclosed embodiment, avoiding unsupported generalisations, and ensuring dependent claims cascade logically from independent claims.

Step 5, Provisional Application (Optional but Recommended)

A provisional application is not examined and does not mature into a granted patent on its own. Its purpose is to establish a priority date at low cost. The applicant then has 12 months to file a complete (standard) application claiming priority from the provisional. The official IP Australia fee for a provisional application is currently under AUD 250, making it an accessible entry point for startups and individual inventors.

The 12-month window is useful for market testing, seeking investor interest or refining the invention, but the provisional specification must adequately describe the invention as it will later be claimed. A poorly drafted provisional can undermine the priority date if it fails to support the claims in the subsequent complete application.

Step 6, Complete (Standard) Patent Application

The complete application includes the full specification (description, claims and abstract), any drawings, and the prescribed forms. It can be filed directly (without a preceding provisional) or within 12 months of the provisional filing date. If claiming convention priority from an overseas application, the complete application must be filed within 12 months of the earliest foreign priority date.

Step 7, Request for Examination and Responding to Objections

Examination is not automatic. The applicant must request examination, which can be done at filing or later. IP Australia may also direct the applicant to request examination. Once requested, examiners typically issue a first examination report within approximately 6–12 months. The applicant has 12 months from the date of that first report to overcome all objections and bring the application into an acceptable form.

Common objections include lack of novelty over cited prior art, lack of inventive step, insufficiency of description, and, increasingly after the March 2026 Manual update, subject-matter eligibility objections for computer-implemented inventions.

Step 8, Acceptance, Opposition and Grant

Once accepted, the application is advertised in the Australian Official Journal of Patents. Third parties have a three-month window to file an opposition. If no opposition is filed (or if the opposition fails), the patent proceeds to grant. The standard patent term is 20 years from the complete application filing date (s 67, Patents Act 1990).

Provisional vs Standard vs PCT, Comparison Table

Cost to File a Patent in Australia, Transparent Fee Breakdown

The cost to file a patent in Australia varies significantly depending on whether you self-file or engage a registered patent attorney. Below is an indicative guide combining IP Australia’s official fees with typical professional-service ranges.

Budgeting tip: A straightforward mechanical invention might cost AUD 10,000–15,000 in total professional fees through to grant. A complex pharmaceutical or biotech patent, with multiple examination responses, divisional strategies and PTE considerations, can exceed AUD 40,000. Factor in maintenance fees across the 20-year life of the patent when assessing return on investment.

Self-filing is possible via IP Australia’s online portal, and the official fees alone are modest. However, the risks of inadequate claims drafting, insufficient disclosure or missed deadlines make professional assistance the default recommendation for commercially significant inventions. Details of current fee schedules are published on the IP Australia patents page.

Patentability in Australia, Key Legal Tests and How to Patent an Idea Successfully

The Five Requirements for Patentability

Under s 18 of the Patents Act 1990, a standard patent must satisfy five core requirements:

• Manner of manufacture (subject-matter eligibility). The claimed invention must be a “manner of manufacture” within the meaning of s 6 of the Statute of Monopolies. This excludes mere discoveries, abstract ideas, laws of nature and (in most formulations) pure business methods.
• Novelty. The invention must be new, it must not have been publicly disclosed anywhere in the world before the priority date (s 7(1)).
• Inventive step. The invention must not be obvious to a person skilled in the relevant art, having regard to the common general knowledge and any document that forms part of the prior-art base (s 7(2)–(3)).
• Usefulness (utility). The invention must have a specific, substantial and credible use.
• Sufficiency of description (enablement). The complete specification must describe the invention fully enough for a skilled person to perform it (s 40).

Patentability of Medical Methods in Australia

Unlike some jurisdictions, Australia does not have a blanket statutory exclusion for methods of medical treatment. The Patents Act 1990 does not list “methods of treatment of the human body by surgery or therapy” among its exclusion categories. The High Court confirmed in Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (2013) that methods of medical treatment can constitute a manner of manufacture. However, examiners scrutinise such claims closely for sufficiency and utility, and the IP Australia Patent Manual update of 16 March 2026 reminds examiners to apply rigorous assessment to claims directed to personalised-medicine algorithms and diagnostic methods implemented on generic computing hardware.

IP Australia Patent Manual Update 2026, What Changed on 16 March

The IP Australia Patent Manual refresh dated 16 March 2026 introduced several changes that directly affect how to patent an idea in Australia going forward. IP Australia published the update alongside a public consultation on its consultation hub, inviting stakeholder feedback on proposed practice changes.

The key changes and their practical implications include:

• Computer-implemented inventions (CII) guidance. The Manual now includes expanded guidance on how examiners should assess whether a claimed computer-implemented invention constitutes a manner of manufacture. Applicants claiming software-based or AI-driven solutions should ensure their specifications articulate a concrete technical problem and a technical solution, not merely the automation of an abstract concept on generic hardware.
• Excess claims reminder process. IP Australia updated its process for issuing excess-claims reminders, streamlining the timeline and aligning reminder triggers with the examination-report cycle. Applicants filing specifications with large claim sets (more than 20 claims) should expect earlier fee reminders and should budget accordingly.
• PTE processing pause and updated practice. In the wake of the Full Federal Court’s decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd, IP Australia issued an official notice in early 2026 indicating that it was reviewing its practice for assessing PTE applications. The March 2026 Manual update formalises revised examiner guidance on how to determine the “earliest first inclusion” date for a pharmaceutical substance on the ARTG, a critical variable in calculating PTE duration. Pharmaceutical applicants with pending or prospective PTE applications should review the updated guidance closely.
• Examination timeline expectations. The Manual reaffirms IP Australia’s target of issuing first examination reports within approximately six months of request in straightforward cases, though complex biotech and pharmaceutical applications may take longer.

Stakeholders can review the full consultation and supporting documents on IP Australia’s consultation page.

Timeline of Key Legislative and Administrative Dates

Pharmaceutical Patents and Patent Term Extensions in Australia, Playbook

Eligibility Criteria for PTE Under the Patents Act

A patent term extension in Australia allows the holder of a standard patent to extend the patent term beyond the default 20 years by up to 5 years. The statutory framework is set out in ss 70–79A of the Patents Act 1990. A PTE is available where:

• The patent claims a pharmaceutical substance per se, or a pharmaceutical substance when produced by a specified process (s 70(2)).
• Goods containing, or consisting of, that substance are included on the Australian Register of Therapeutic Goods (ARTG) (s 70(3)).
• At least five years has elapsed between the patent’s filing date and the date of first inclusion on the ARTG (s 71).
• The PTE application is filed within six months of the later of the date of grant of the patent or the date of first inclusion on the ARTG (s 71(2)).

The extended term is calculated by reference to the period between the patent filing date and the earliest first inclusion on the ARTG, reduced by five years, subject to the five-year cap.

Otsuka v Sun Pharma, Impact on PTE Practice

The Full Federal Court’s 2025 decision in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd addressed the interpretation of “earliest first inclusion” on the ARTG. The court’s reasoning clarified that the relevant date is the date on which goods containing any pharmaceutical substance claimed in the patent are first included on the ARTG, not necessarily the specific formulation or indication for which the patentee’s product received marketing approval.

This ruling has practical consequences. IP Australia issued an official notice acknowledging the decision and confirming a review of its assessment practice. Industry observers expect that applicants whose patents cover broad pharmaceutical substance claims will need to pay closer attention to whether earlier ARTG listings of the same substance, potentially by third parties or for different indications, may affect the calculation of PTE duration.

Evidence and Drafting to Preserve PTE Eligibility

Pharmaceutical applicants should adopt a deliberate drafting strategy from the outset to preserve PTE eligibility:

• Claim the substance per se. A PTE is only available for patents that claim the pharmaceutical substance itself, not merely a method of using it or a formulation.
• Track ARTG inclusion dates rigorously. Maintain a register of all ARTG listings for the relevant substance, including listings by licensees, generic entrants or for different therapeutic indications.
• File the PTE application promptly. The six-month filing window under s 71(2) is strict. Missing it forfeits any PTE entitlement.
• Prepare supporting evidence early. Evidence of regulatory timelines, including TGA evaluation periods and any delays attributable to regulatory processes, strengthens the application and may assist in defending the calculation of the extended term.

How Long Is a Pharmaceutical Patent in Australia?

A standard pharmaceutical patent in Australia lasts 20 years from its complete application filing date. With a PTE, the total term can extend to a maximum of 25 years. The actual extension depends on the time elapsed between the filing date and first ARTG inclusion, minus five years, capped at five additional years. For a product that took 12 years from patent filing to ARTG listing, the PTE would be 12 − 5 = 7 years, but capped at 5, yielding a total patent term of 25 years.

International Filing and the PCT Pathway from Australia

Applicants seeking patent protection beyond Australia can file an international application under the Patent Cooperation Treaty (PCT). The PCT application must be filed within 12 months of the earliest priority date (typically the provisional application date). It preserves the right to enter the national or regional phase in over 150 member states, with national-phase entry deadlines generally falling 30 or 31 months from the priority date.

A significant development for 2026 is the EPO ISA/IPEA pilot programme, which commenced on 1 March 2026. Under this pilot, Australian applicants filing PCT applications through IP Australia as receiving office can now designate the European Patent Office as the International Searching Authority (ISA) or International Preliminary Examining Authority (IPEA). This gives applicants access to EPO search and examination quality, valuable for inventions with primary commercial markets in Europe. The pilot operates alongside IP Australia’s existing role as ISA/IPEA.

Applicants should discuss the strategic choice of ISA with their patent attorney, balancing search quality, cost and the jurisdictions in which grant is ultimately sought.

Post-Grant Maintenance, Enforcement and Common Traps

Once granted, a standard patent must be maintained by paying annual renewal fees to IP Australia. Renewals begin from the 5th anniversary of the filing date and escalate over time, from approximately AUD 300 in the early years to over AUD 1,750 in later years. Failure to pay by the due date (with applicable grace periods) results in the patent lapsing.

Enforcement of a granted patent is through proceedings in the Federal Court of Australia. Patent holders can seek injunctions, damages or an account of profits. However, patents are also vulnerable to revocation, either through a post-grant opposition (within 3 months of acceptance advertisement) or through court proceedings brought by any person challenging validity.

Common traps that undermine granted patents include insufficient disclosure in the specification (making the patent vulnerable to revocation for insufficiency), overbroad claims unsupported by the description, and failure to disclose relevant prior art known to the applicant during prosecution.

Common Mistakes and Practical Tips

• Insufficient disclosure. Ensure the specification enables reproduction of the invention across the full scope of the claims. For pharmaceutical inventions, include representative experimental data.
• Overbroad claims without support. Each independent claim should be fully supported by the description. Dependent claims should narrow the scope methodically.
• Missed deadlines. The 12-month provisional-to-complete deadline, the 12-month examination response period and the 6-month PTE filing window are all non-negotiable. Implement a robust docketing system.
• Poor ownership documentation. Disputes over inventorship or entitlement can derail a patent years after grant. Execute assignment agreements before filing.
• Ignoring the updated Patent Manual. The March 2026 revisions affect CII prosecution and PTE assessment. Applicants who draft specifications without accounting for updated examiner guidance risk additional objections and delays.

Conclusion, Next Steps for Patenting Your Idea in Australia

Knowing how to patent an idea in Australia means understanding a structured process: assess patentability, search the prior art, draft a robust specification, file strategically (provisional first, then complete), navigate examination, and maintain the granted patent. The 16 March 2026 Patent Manual update and the Otsuka v Sun Pharma decision add layers of complexity for pharmaceutical and technology applicants that reward early professional engagement. For those with significant commercial interests, whether in pharma lifecycle management, software innovation or deep-tech R&D, consulting an experienced Australian IP lawyer at the outset remains the single most cost-effective step you can take.

Sources

1. IP Australia, Patents
2. IP Australia, Patent Manual Update (March 2026) / Consultation Page
3. IP Australia, Official Notice: Otsuka v Sun Pharma
4. Federal Register of Legislation, Patents Act 1990 (Cth)
5. Business.gov.au, Patents
6. Actuate IP, How to Patent an Idea in Australia
7. BRM Patent Attorneys, How to Patent an Idea or Invention
8. Dentons, Patent Term Extension in Australia: Implications of Otsuka v Sun Pharma